Why the study?
Although guidelines provide a stage-based framework for managing cardiovascular-kidney-metabolic (CKM) syndrome, the potential of lifestyle interventions to prevent cardiac damage across CKM stages remains incompletely defined.
Do dietary and behavioural lifestyle interventions prevent myocardial remodelling, subclinical cardiac injury, and progression to clinical cardiovascular disease in patients across CKM syndrome Stages 0–4?
Do dietary and behavioural lifestyle interventions prevent myocardial remodelling, subclinical cardiac injury, and progression to clinical cardiovascular disease in patients across CKM syndrome Stages 0–4?
This narrative review highlights that while lifestyle interventions improve cardiometabolic risk factors across CKM syndrome stages 0–4, direct evidence for stage-specific prevention or reversal of cardiac damage remains limited.
Answers are grounded in this paper and cite their sources.
Dietary and behavioural interventions in CKM stages need clarification; leaves open optimal strategies to prevent cardiac damage pending prospective trials.
Cardiovascular–kidney–metabolic (CKM) syndrome integrates excess adiposity, metabolic dysfunction, chronic kidney disease, and cardiovascular disease within a progressive clinical continuum. The 2026 AHA/ACC/ADA/ASN guideline provides a stage-based framework for prevention and management, yet the potential of lifestyle interventions to prevent cardiac damage remains incompletely defined. This narrative review examines dietary and behavioural interventions across CKM Stages 0–4, focusing on myocardial remodelling, subclinical cardiac injury, and progression to clinical cardiovascular disease. At Stage 0, healthy behaviours aim to preserve optimal CKM health; at Stage 1, weight management targets excess or dysfunctional adiposity and metabolic progression. At Stage 2, dietary modification, physical activity, sodium reduction, and other lifestyle measures complement treatment of established metabolic and kidney risk factors. At Stage 3, structured interventions may attenuate subclinical cardiac and vascular injury alongside risk-guided pharmacotherapy, although evidence for preventing clinical progression remains limited. At Stage 4, lifestyle interventions support secondary prevention, rehabilitation, functional capacity, and quality of life. Evidence is strongest for cardiometabolic risk-factor improvement and selected cardiovascular outcomes, whereas direct evidence of stage-specific prevention or reversal of cardiac damage is limited. Integrating sustained lifestyle support with CKM staging may improve the precision of preventive care.
No takes yet. Share an insight, caveat, or question.
Iliakis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: